Plus Therapeutics Secures AMA Billing Code for CNSide; Stock Dips 4.8%

Plus Therapeutics (PSTV) announced it has secured a dedicated billing code from the American Medical Association (AMA) for its CNSide diagnostic platform. The new code, 0640U, is designed to streamline the reimbursement process for healthcare providers using the system to detect tumor cells in cerebrospinal fluid. This operational milestone is expected to enhance the company's commercial infrastructure and increase market penetration within the CNS oncology sector. However, the billing code is not scheduled to become effective until July 1, 2026, creating a significant lead time before its full impact is realized. Despite the positive long-term implications for commercial scaling, the company's stock experienced a decline of 4.80% following the announcement. Investors appear to be weighing the delayed implementation against the immediate operational progress in the biotech firm's diagnostic portfolio.